Helen Katrina Tayton-Martin's Net Worth
$3.88 Million
Who is Helen Katrina Tayton-Martin?
Helen Katrina Tayton-Martin has an estimated net worth of $3.88 Million. This is based on reported shares across multiple companies, which include Adaptimmune Therapeutics PLC, and Trillium Therapeutics Inc..
SEC CIK
Helen Katrina Tayton-Martin's CIK is 0001661780
Past Insider Trading and Trends
2021 was Helen Katrina Tayton-Martin's most active year for acquiring shares with 3 total transactions. Helen Katrina Tayton-Martin's most active month to acquire stocks was the month of December. 2020 was Helen Katrina Tayton-Martin's most active year for disposing of shares, totalling 3 transactions. Helen Katrina Tayton-Martin's most active month to dispose stocks was the month of December. 2021 saw Helen Katrina Tayton-Martin paying a total of $280,245.00 for 3,114,528 shares, this is the most they've acquired in one year. In 2020 Helen Katrina Tayton-Martin cashed out on 300,000 shares for a total of $2,198,180.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Adaptimmune Therapeutics PLC (ADAP) Snapshot price: $1.09
Chief Business & Strgy OfficerHelen Katrina Tayton-Martin owns 1,800,000 units of Ordinary Shares with a nominal value of GBP0.001 per share which is worth $1,962,000.00. Helen Katrina Tayton-Martin used to own units in American Depositary Shares but no longer holds any shares there. From 2016 to 2024 Helen Katrina Tayton-Martin acquired a total of 1,785,000 shares in Adaptimmune Therapeutics PLC at a cost of $280,245.00, Helen also disposed a total of 300,000 shares of Adaptimmune Therapeutics PLC equalling to $2,198,180.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
| +11,900.00% | 1.78M |
$0.16 | $280,245.00 | 1.8M |
Mar 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 11
| |||
Form 4
| -100.00% | -200.00K |
$8.74 | -$1,748,180.00 |
0
|
Scheduled
|
Aug 3
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 16
| |||
Form 4
| -100.00% | -100.00K |
$4.50 | -$450,000.00 |
0
|
Scheduled
|
Jan 13
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Trillium Therapeutics Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||